PortfoliosLab logoPortfoliosLab logo
DAKT vs. HRMY
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

DAKT vs. HRMY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Daktronics, Inc. (DAKT) and Harmony Biosciences Holdings, Inc. (HRMY). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, DAKT achieves a -2.12% return, which is significantly higher than HRMY's -7.94% return.


DAKT

1D
-3.78%
1M
-4.63%
YTD
-2.12%
6M
4.48%
1Y
27.30%
3Y*
47.50%
5Y*
24.69%
10Y*
13.32%

HRMY

1D
0.85%
1M
14.26%
YTD
-7.94%
6M
-10.50%
1Y
7.45%
3Y*
-1.48%
5Y*
3.10%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

DAKT vs. HRMY - Yearly Performance Comparison


2026 (YTD)202520242023202220212020
DAKT
Daktronics, Inc.
-2.12%17.26%98.82%200.71%-44.16%7.91%14.99%
HRMY
Harmony Biosciences Holdings, Inc.
-7.94%8.75%6.53%-41.38%29.22%17.95%-9.60%

Correlation

The correlation between DAKT and HRMY is 0.11, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.11

Correlation (3Y)
Calculated over the trailing 3-year period

0.16

Correlation (5Y)
Calculated over the trailing 5-year period

0.16

Correlation (All Time)
Calculated using the full available price history since Aug 19, 2020

0.15

Fundamentals

Market Cap

DAKT:

$948.77M

HRMY:

$2.02B

EPS

DAKT:

$0.92

HRMY:

$2.48

PE Ratio

DAKT:

21.10

HRMY:

13.88

PEG Ratio

DAKT:

0.06

HRMY:

0.14

PS Ratio

DAKT:

1.14

HRMY:

2.25

PB Ratio

DAKT:

3.15

HRMY:

2.22

Total Revenue (TTM)

DAKT:

$838.71M

HRMY:

$899.11M

Gross Profit (TTM)

DAKT:

$229.01M

HRMY:

$688.25M

EBITDA (TTM)

DAKT:

$75.59M

HRMY:

$221.74M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

DAKT vs. HRMY — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

DAKT
DAKT Risk / Return Rank: 6161
Overall Rank
DAKT Sharpe Ratio Rank: 6262
Sharpe Ratio Rank
DAKT Sortino Ratio Rank: 6262
Sortino Ratio Rank
DAKT Omega Ratio Rank: 5959
Omega Ratio Rank
DAKT Calmar Ratio Rank: 6262
Calmar Ratio Rank
DAKT Martin Ratio Rank: 5858
Martin Ratio Rank

HRMY
HRMY Risk / Return Rank: 4747
Overall Rank
HRMY Sharpe Ratio Rank: 4949
Sharpe Ratio Rank
HRMY Sortino Ratio Rank: 4545
Sortino Ratio Rank
HRMY Omega Ratio Rank: 4646
Omega Ratio Rank
HRMY Calmar Ratio Rank: 4848
Calmar Ratio Rank
HRMY Martin Ratio Rank: 4848
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

DAKT vs. HRMY - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Daktronics, Inc. (DAKT) and Harmony Biosciences Holdings, Inc. (HRMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


DAKTHRMYDifference
Sharpe ratioReturn per unit of total volatility

+0.40

Sortino ratioReturn per unit of downside risk

+0.74

Omega ratioGain probability vs. loss probability

1.15

1.08

+0.07

Calmar ratioReturn relative to maximum drawdown

0.88

0.22

+0.66

Martin ratioReturn relative to average drawdown

1.43

0.40

+1.03

DAKT vs. HRMY - Sharpe Ratio Comparison

The current DAKT Sharpe Ratio is 0.58, which is higher than the HRMY Sharpe Ratio of 0.18. The chart below compares the historical Sharpe Ratios of DAKT and HRMY, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

DAKT vs. HRMY - Drawdown Comparison

The maximum DAKT drawdown since its inception was -92.96%, which is greater than HRMY's maximum drawdown of -68.48%. Use the drawdown chart below to compare losses from any high point for DAKT and HRMY.


Loading charts...

Drawdown Indicators


DAKTHRMYDifference

Max Drawdown

Largest peak-to-trough decline

-92.96%

-68.48%

-24.48%

Max Drawdown (1Y)

Largest decline over 1 year

-31.34%

-34.49%

+3.15%

Max Drawdown (3Y)

Largest decline over 3 years

-42.00%

-50.81%

+8.81%

Max Drawdown (5Y)

Largest decline over 5 years

-73.48%

-68.48%

-5.00%

Max Drawdown (10Y)

Largest decline over 10 years

-82.34%

Current Drawdown

Current decline from peak

-30.22%

-43.44%

+13.22%

Average Drawdown

Average peak-to-trough decline

-50.10%

-35.31%

-14.79%

Ulcer Index

Depth and duration of drawdowns from previous peaks

19.15%

18.90%

+0.25%

Volatility

DAKT vs. HRMY - Volatility Comparison

Daktronics, Inc. (DAKT) has a higher volatility of 13.48% compared to Harmony Biosciences Holdings, Inc. (HRMY) at 9.97%. This indicates that DAKT's price experiences larger fluctuations and is considered to be riskier than HRMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


DAKTHRMYDifference

Volatility (1M)

Calculated over the trailing 1-month period

13.48%

9.97%

+3.51%

Volatility (6M)

Calculated over the trailing 6-month period

30.07%

30.03%

+0.04%

Volatility (1Y)

Calculated over the trailing 1-year period

47.57%

41.74%

+5.83%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

52.31%

50.14%

+2.17%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

45.93%

52.34%

-6.41%

Dividends

DAKT vs. HRMY - Dividend Comparison

Neither DAKT nor HRMY has paid dividends to shareholders.


PositionTTM20252024202320222021202020192018201720162015
DAKT
Daktronics, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%1.07%3.61%3.78%3.07%3.18%4.59%
HRMY
Harmony Biosciences Holdings, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials

DAKT vs. HRMY - Financials Comparison

This section allows you to compare key financial metrics between Daktronics, Inc. and Harmony Biosciences Holdings, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


100.00M150.00M200.00M250.00M20222023202420252026
208.61M
215.39M
(DAKT) Total Revenue
(HRMY) Total Revenue
Values in USD except per share items

DAKT vs. HRMY - Profitability Comparison

The chart below illustrates the profitability comparison between Daktronics, Inc. and Harmony Biosciences Holdings, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

20.0%30.0%40.0%50.0%60.0%70.0%80.0%20222023202420252026
28.0%
79.3%
Portfolio components
DAKT - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Daktronics, Inc. reported a gross profit of 58.48M and revenue of 208.61M. Therefore, the gross margin over that period was 28.0%.

HRMY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Harmony Biosciences Holdings, Inc. reported a gross profit of 170.88M and revenue of 215.39M. Therefore, the gross margin over that period was 79.3%.

DAKT - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Daktronics, Inc. reported an operating income of 14.09M and revenue of 208.61M, resulting in an operating margin of 6.8%.

HRMY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Harmony Biosciences Holdings, Inc. reported an operating income of 37.29M and revenue of 215.39M, resulting in an operating margin of 17.3%.

DAKT - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Daktronics, Inc. reported a net income of 8.42M and revenue of 208.61M, resulting in a net margin of 4.0%.

HRMY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Harmony Biosciences Holdings, Inc. reported a net income of 32.49M and revenue of 215.39M, resulting in a net margin of 15.1%.


Frequently Asked Questions


DAKT and HRMY have a correlation of 0.11, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

DAKT has higher volatility (13.48%) compared to HRMY (9.97%). In terms of maximum drawdown, DAKT dropped -92.96% vs HRMY's -68.48%.

DAKT currently has the higher Sharpe Ratio (0.58 vs 0.18), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for DAKT and HRMY

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer